Bioadaptives, Inc. (BDPT)
BDPT is quoted over the counter, not listed on an exchange. Bioadaptives, Inc. files reports with the SEC; the numbers below come from SEC filings and from daily closes, each with its source.
Closes: Yahoo Finance daily closes, last bar 2026-11-13.
Profile
| Field | Value |
|---|---|
| Ticker | BDPT, quoted over the counter |
| SEC CIK | 0001575142 |
| OTC Markets tier | OTCID (price source, 2026-11-13) |
| SEC industry code | Pharmaceutical Preparations |
| Business address | Las Vegas, NV |
| Incorporated in | DE |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "The ability to successfully resolve these factors raises substantial doubt about the Company's ability to continue as a going concern." | 10-Q 2026-08-19 |
| Cash and burn | $29K cash; operating cash flow -$109K a quarter. | Report 2026-06-30 |
| Shares outstanding | 196,926,762 (2026-08-13); 9,948,659 a year earlier; 776,464,023 three years earlier. 3y figure adjusted for splits (1-for-150 overall). | Cover page 2026-08-13 |
| Reverse splits, 3 years | 1; latest 1-for-300 on 2024-11-21 | Source 2024-11-21 |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Boladale Lawal & Co ( Chartered Accountants), Lagos, Nigeria | PCAOB Form AP 2026-04-19 |
| Late filings, 12 months | 2 NT notices | NT 10-Q 2026-08-14 |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q2 2026 2026-06-30 | $5K | $150K | -$44K | $29K | $1.0M | $26K | 10-Q 2026-08-19 |
| Q1 2026 2026-03-31 | $6K | -$111K | -$85K | $74K | $881K | $24K | 10-Q 2026-05-15 |
| Q4 2025 2025-12-31 | $10K | -$823K | -$156K | $215K | $737K | $18K | 10-K 2026-04-14 |
| Q3 2025 2025-09-30 | $5K | -$380K | -$151K | $59K | $391K | $8K | 10-Q 2025-11-14 |
| Q2 2025 2025-06-30 | $3K | -$158K | -$111K | $211K | $343K | $3K | 10-Q 2026-08-19 |
| Q1 2025 2025-03-31 | $0 | -$197K | -$98K | $40K | $343K | $675 | 10-Q 2026-05-15 |
| Q4 2024 2024-12-31 | $0 | -$372K | -$101K | $262K | $954K | $13K | 10-K 2026-04-14 |
| Q3 2024 2024-09-30 | $0 | -$38K | -$56K | $44K | $343K | $20K | 10-Q 2025-11-14 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 1-A | 2023-10-11 |
| Latest annual report | 10-K | 2026-04-14 |
| Latest quarterly / interim | 10-Q | 2026-11-16 |
| Latest current report | 8-K | 2026-11-04 |
Source: SEC EDGAR submissions feed, 177 recent filings. All filings on EDGAR.
The full dossier has every filing, quarterly and annual financials, the health record and a price chart.
Open the full dossier